The heterogeneity of CRCI may be rectified by COMT (rs165599, rs737865) polymorphism, and this rectification may possibly show that COMT polymorphism is a risk leading to a lower memory performance in breast cancer patients with disparate HER2. The gene discussed is ERBB2; the disease is breast carcinoma.